Literature DB >> 9469527

Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain.

Jürgen Lorenz1, Helge Beck, Burkhart Bromm.   

Abstract

This paper investigates subjective, behavioral and neurophysiological changes due to treatment with oral sustained-release morphine in six patients with severe non-malignant pain. Patients rated their mood and clinical pain on visual analog scales (VAS). Experimental pain reactions were quantified by ratings on categorical scales and evoked cerebral potentials (LEP) in response to standardized laser stimuli. A standard auditory oddball task provided reaction time (RT), errors, N1 and P2 of late auditory evoked potentials (AEP), and a P300 component. It was used to measure vigilance and cognitive performance. In parallel with clinical pain reduction, laser pain ratings and LEP amplitudes were significantly reduced. In contrast, auditory P2 and P300 amplitude were found to be even enlarged under morphine. RT and mood also failed to indicate any sedation. It is concluded that LEP indicated the analgesic morphine effects whereas late potentials and P300 from auditory stimuli reflected the perceptual-cognitive status which, instead of being deteriorated by morphine-induced sedation, improved probably due to the removal of pain as a mental stressor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9469527     DOI: 10.1016/S0304-3959(97)00123-1

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  26 in total

1.  Placebo effects in laser-evoked pain potentials.

Authors:  Tor D Wager; Dagfinn Matre; Kenneth L Casey
Journal:  Brain Behav Immun       Date:  2006-03-29       Impact factor: 7.217

Review 2.  The cognitive effects of opioids in cancer: a systematic review.

Authors:  Geana Paula Kurita; Lena Lundorff; Cibele Andrucioli de Mattos Pimenta; Per Sjøgren
Journal:  Support Care Cancer       Date:  2008-09-02       Impact factor: 3.603

Review 3.  Pain in nursing home residents: management strategies.

Authors:  D K Weiner; J T Hanlon
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  [Safety-relevant performance of patients on chronic opioid therapy].

Authors:  M Strumpf; A Willweber-Strumpf; K W Herberg; M Zenz
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

5.  Does mutual compensation of the cognitive effects induced by pain and opioids exist? An experimental study.

Authors:  Geana Paula Kurita; Lasse Paludan Malver; Trine Andresen; Romanas Polianskis; Asbjørn Mohr Drewes; Lona Christrup; Jette Højsted; Per Sjøgren
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

6.  Pain, Fatigue, and Cognitive Symptoms Are Temporally Associated Within but Not Across Days in Multiple Sclerosis.

Authors:  Anna L Kratz; Susan L Murphy; Tiffany J Braley
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

7.  Pain differs from non-painful attention-demanding or stressful tasks in its effect on postural control patterns of trunk muscles.

Authors:  G Lorimer Moseley; M K Nicholas; Paul W Hodges
Journal:  Exp Brain Res       Date:  2003-12-19       Impact factor: 1.972

Review 8.  Electroencephalography and analgesics.

Authors:  Lasse Paludan Malver; Anne Brokjaer; Camilla Staahl; Carina Graversen; Trine Andresen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

9.  Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in diabetic neuropathic pain.

Authors:  Franco Cauda; Katiuscia Sacco; Federico D'Agata; Sergio Duca; Dario Cocito; Giuliano Geminiani; Filippo Migliorati; Gianluca Isoardo
Journal:  BMC Neurosci       Date:  2009-11-26       Impact factor: 3.288

10.  Morphine modulation of pain processing in medial and lateral pain pathways.

Authors:  Jin-Yan Wang; Jin Huang; Jing-Yu Chang; Donald J Woodward; Fei Luo
Journal:  Mol Pain       Date:  2009-10-13       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.